Figure 4. VHL-deficient renal carcinoma cells are hypersensitive to IR and PARP inhibitors compared to VHL^WT-complemented cells.

(A, B) Clonogenic survival in 786-O^VHL–/– and 786-O+VHL^WT cells (A) or RCC4^VHL–/– and RCC4+VHL^WT cells (B) treated with ionizing radiation. (C, D) Clonogenic survival in 786-O^VHL–/– and 786-O+VHL^WT cells (C) or RCC4^VHL–/– and RCC4+VHL^WT cells (D) exposed continuously to the PARP inhibitor Olaparib. (E, F) Clonogenic survival in 786-O^VHL–/– and 786-O+VHL^WT cells (E) or RCC4^VHL–/– and RCC4+VHL^WT cells (F) exposed continuously to the PARP inhibitor BMN-673. Points, mean of 3 to 6 replicates; error bars, SEM.